Ionis Pharmaceuticals Stock Price

0.46 (1.25%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Ionis Pharmaceuticals Inc IONS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.46 1.25% 37.14 00:00:13
Open Price Low Price High Price Close Price Prev Close
36.56 36.555 37.825 37.14 36.68
Bid Price Ask Price Spread News
35.02 40.39 5.37 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
10,086 996,382 $ 37.30 $ 37,161,814 - 34.43 - 64.37
Last Trade Time Type Quantity Stock Price Currency
19:42:18 1 $ 37.14 USD


Draw Mode:

Ionis Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 5.24B 140.96M 118.92M $ 729.26M $ -615.64M -3.16 -10.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -31.96k 0.50%

more financials information »

Ionis Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IONS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week37.5238.5035.7637.25979,012-0.38-1.01%
1 Month40.2240.2734.6537.371,046,899-3.08-7.66%
3 Months37.5340.3334.4337.141,623,247-0.39-1.04%
6 Months61.0062.6534.4342.131,488,431-23.86-39.11%
1 Year58.3264.3734.4346.291,250,203-21.18-36.32%
3 Years44.7288.707534.4354.541,103,774-7.58-16.95%
5 Years37.1688.707524.5850.031,256,278-0.02-0.05%

Ionis Pharmaceuticals Description

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Your Recent History
Ionis Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210801 07:59:34